[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasolabial-folds-wrinkles\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasolabial-folds-wrinkles":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,60,84,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100628868","a-prospective-clinical-investigation-of-dmfi300-for-treating-nasolabial-folds-100628868",false,"NCT07467239","A Prospective Clinical Investigation of DMFI300 for Treating Nasolabial Folds","A Prospective, Participant- and Evaluator-blinded, Randomized, Controlled, Split-face Clinical Investigation to Evaluate the Performance and Safety of Polycaprolactone 300 (DMFI300) for the Treatment of Nasolabial Folds","Inclusion Criteria:\n\n* Men and women aged 18-70 years.\n* Score of 3 to 4 on the Wrinkle Severity Rating Scale (WSRS) for both nasolabial folds.\n* Willing and able to provide written informed consent.\n* Willing to comply with study procedures and follow-up visits.\n* Willing to refrain from other facial cosmetic procedures affecting the nasolabial folds during the study.\n\nExclusion Criteria:\n\n* Use of antiplatelet agents, vitamin E, or NSAIDs within 2 weeks before screening or planned use within 2 weeks after treatment.\n* History or presence of bleeding disorders.\n* Participation in another clinical investigation within 1 month prior to screening.\n* Pregnant or breastfeeding women, or women planning pregnancy during the study.\n* Women of childbearing potential not using an effective method of contraception.","ALL","18 Years","70 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a prospective, randomized, controlled clinical investigation designed to evaluate the performance and safety of DMFI300 for the treatment of nasolabial folds. 30 adult participants will receive treatment with the investigational device and the comparator device using a split-face design. The study will assess wrinkle severity using validated aesthetic evaluation scales, as well as overall safety.",[27],"Nasolabial Folds, Wrinkles","RECRUITING","2026-03-09",{"date":31,"type":32},"2026-03-12","ACTUAL",{"date":34,"type":32},"2026-03-02",{"date":36,"type":21},"2027-05-31",{"name":38,"class":39},"Samyang Biopharmaceuticals Corporation","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":40},"100615451","a-prospective-clinical-investigation-of-dmfi150-for-treating-nasolabial-folds-100615451","NCT07292779","A Prospective Clinical Investigation of DMFI150 for Treating Nasolabial Folds","A Prospective, Clinical Investigation to Evaluate the Performance and Safety of DMFI150 for the Treatment of Nasolabial Folds","Inclusion Criteria:\n\n* Men and women aged 18-70 years.\n* Score of 3 to 4 on the WSRS (1 = absent, 2 = mild, 3 = moderate, 4 = severe, and 5 = extreme) for both nasolabial folds.\n* Able and willing to provide written informed consent.\n* Willing to refrain from facial cosmetic procedures during the study.\n\nExclusion Criteria:\n\n* Use of antiplatelet agents, vitamin E, or NSAIDs within 2 weeks before screening or 2 weeks after treatment.\n* History or current bleeding disorders.\n* Participation in another clinical trial within 1 month before screening.\n* Pregnant or breastfeeding women, or planning pregnancy.\n* Women of childbearing potential not using effective contraception.",{"count":20,"type":21},[24],"This is a prospective clinical investigation designed to evaluate the performance and safety of DMFI150 for the treatment of nasolabial folds. 30 adult participants will receive a single treatment with the investigational device. The study will assess wrinkle severity using validated aesthetic evaluation scales, as well as overall safety.",[27],"2026-03-04",{"date":54,"type":32},"2026-03-05",{"date":56,"type":32},"2025-11-24",{"date":58,"type":21},"2026-12",{"name":38,"class":39},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":16,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":64,"conditions":73,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100624650","study-of-diosha-s-lido-injection-vs-youthfill-fine-with-lidocaine-in-treating-moderate-to-severe-nasolabial-folds-100624650","NCT07412392","Study of DIOSHA S Lido Injection vs. YOUTHFILL Fine With Lidocaine in Treating Moderate to Severe Nasolabial Folds","A Multi Center, Randomized, Subject & Independent Evaluator-blinded, Matched Pairs, Active Controlled, Non-inferiority, Pivotal Study to Evaluate the Efficacy and Safety of Injection With DIOSHA S Lido as Compared to YOUTHFILL(YOUTHFILL Fine With Lidocaine) in Temporary Correction of Moderate to Severe Nasolabial Folds","Inclusion Criteria:\n\n* Adults aged 19 to 75 years\n* Voluntarily provided written informed consent\n* Moderate to severe symmetrical nasolabial folds (WSRS score 3 or 4 on both sides)\n* Agree to discontinue other facial dermatologic treatments (e.g., fillers, botulinum toxin, laser) during the study\n* Able to understand instructions and comply with study procedures\n\nExclusion Criteria:\n\n* Active facial skin disease, infection, or untreated scars in the treatment area\n* History of severe allergy or hypersensitivity to device components\n* Facial aesthetic or invasive procedures in the treatment area within 6 months prior to screening\n* Use of prohibited medications within required washout periods\n* Participation in another interventional clinical trial within 4 weeks prior to screening or during the study\n* Pregnancy, breastfeeding, or non-compliance with contraception requirements\n* Any condition deemed inappropriate by the investigator",true,"19 Years","75 Years",{"count":71,"type":21},60,[24],[27],"NOT_YET_RECRUITING","2026-02-09",{"date":77,"type":32},"2026-02-17",{"date":79,"type":21},"2026-02-27",{"date":81,"type":21},"2027-07-30",{"name":83,"class":39},"Hyundae Meditech",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":68,"maxAge":69,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":88,"conditions":94,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100613377","study-of-jtm104-injection-vs-juvederm-in-treating-moderate-to-severe-nasolabial-folds-100613377","NCT07265791","Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds","Multicenter, Randomized, Subject & Independent Evaluator-blind, Matched Pairs, Active-controlled, Non-inferiority, Pivotal Study to Evaluate the Efficacy and Safety of Injection With JTM104 as Compared to Juvederm® ULTRA PLUS XC in Temporary Correction of Moderate to Severe Nasolabial Folds","Inclusion Criteria:\n\n* Adults aged 19 to 75 years\n* Voluntarily provided written informed consent\n* Moderate to severe symmetrical nasolabial folds (WSRS score 3 or 4 on both sides)\n* Agree to discontinue other facial dermatologic treatments (e.g., fillers, botulinum toxin, laser) during the study\n* Able to understand instructions and comply with study procedures\n\nExclusion Criteria:\n\n* Untreated scars or facial skin infections\u002Fdiseases affecting the mid\u002Flower face within the past year\n* History of severe allergy or hypersensitivity to device components\n* Facial invasive procedures within the past 6 months (including surgery, laser, botulinum toxin)\n* Use of certain medications (anticoagulants, immunosuppressants, steroids) within specified washout periods\n* Participation in other interventional clinical trials within 4 weeks before screening or during study\n* Non-compliance with contraception requirements or pregnancy\u002Flactation during study\n* Deemed unsuitable by investigator for any other reason",{"count":92,"type":21},100,[24],[27],{"date":96,"type":32},"2025-12-05",{"date":98,"type":21},"2026-01-03",{"date":100,"type":21},"2027-01-31",{"name":102,"class":39},"Jetema Co., Ltd.",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":67,"sex":16,"minAge":68,"maxAge":18,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":40},"100584164","phase-2-purpose-of-this-study-is-the-demonstration-of-safety-and-efficacy-of-the-dermal-fillers-dxp01-temporary-improvement-of-moderate-to-severe-nasolabial-folds-100584164","NCT06885775","Purpose of This Study is the Demonstration of Safety and Efficacy of the Dermal Fillers DXP01 Temporary Improvement of Moderate to Severe Nasolabial Folds","A Multicenter, Randomized, Evaluator- and Subject-blinded, Active-controlled, Paired, Confirmatory Clinical Trial to Compare and Evaluate the Efficacy and Safety of DXP01 Versus Juvéderm® ULTRA 3 in Adults Requiring the Temporary Improvement of Moderate to Severe Nasolabial Folds","DXP01","Inclusion Criteria:\n\n1. Males and females aged 19 to 70 years.\n2. Subjects with nasolabial folds (NLF) on both sides scored at 3 or 4 on the WSRS (Wrinkle Severity Rating Scale) as evaluated by the investigator at screening (both sides do not need to have the same score but must fall within the 3-4 range).\n3. Subjects with visually symmetrical nasolabial folds (NLF) on both sides.\n4. Subjects who can comply with the clinical trial procedures and will not undergo any facial cosmetic procedures\u002Fsurgeries contraindicated for combination therapy during the clinical trial.\n5. Males and females of childbearing potential who agree to use medically accepted contraception\\* during the clinical trial period. (\\*Hormonal contraception, intrauterine device (IUD) or intrauterine system (IUS), tubal ligation, double-barrier methods (such as combining cervical cap or diaphragm with male condom), or single-barrier methods combined with spermicide).\n6. Subjects who have received a detailed explanation of this clinical trial, understand it, voluntarily decide to participate, and provide written consent.\n7. For women of childbearing potential, individuals who test negative for pregnancy prior to the administration of the investigational product.\n\nExclusion Criteria:\n\n1. Subjects with localized wounds or active infections (such as cysts, acne, rashes, hives, etc.) in the nasolabial fold area.\n2. Subjects with acute, chronic, or recurrent skin conditions (whether infectious or non-infectious).\n3. Subjects with scars or abnormal skin findings (such as moles, erythema, or telangiectasia) in the nasolabial fold area that may affect treatment outcomes.\n4. Subjects with a history of keloid formation, hyperpigmentation, or hypertrophic scars.\n5. Subjects with a history of bleeding disorders (such as liver disease, clotting factor deficiencies, etc.).\n6. Subjects with a history of herpetic rash.\n7. Subjects with connective tissue diseases, autoimmune diseases, or suspected immune deficiencies (such as Sjögren's syndrome, systemic lupus erythematosus, etc.).\n8. Subjects with active sepsis, sarcoidosis, infective endocarditis, or confirmed infections regardless of location, type, or size.\n9. Subjects with known allergies or hypersensitivity reactions, either localized or systemic, to the components of the investigational medical device or amide-type local anesthetics.\n10. Subjects who tested positive in skin patch tests for either the investigational device or control device.\n11. Subjects with a significant history of allergies or anaphylaxis that could affect this clinical trial.\n12. Subjects with clinically significant disorders in the cardiovascular, gastrointestinal, respiratory, endocrine, or central nervous systems.\n13. Subjects with a history of malignancy within 5 years of screening (except for those with basal cell carcinoma, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, thyroid cancer, or prostate cancer, provided there has been no recurrence for over 3 years after complete remission, as judged by the investigator).\n14. Subjects suffering from untreated epilepsy.\n15. Subjects suffering from porphyria.\n16. Subjects with a history of alcohol or drug addiction.\n17. Subjects with a history of psychiatric disorders that, in the investigator's opinion, could significantly affect this clinical trial.\n18. Subjects who have undergone cosmetic procedures contraindicated for this clinical trial within 24 weeks of screening (except for upper eyelid surgery, rhinoplasty performed more than 24 months postoperatively, or lower eyelid correction).\n19. Subjects who have undergone skin augmentation or permanent\u002Fsemi-permanent implant-based cosmetic surgery (such as fillers based on CaHA, PLLA, PMMA, etc.) or PCL fillers or HA fillers on the face within 12 months of screening - CaHA (calcium hydroxyl apatite), PLLA (poly L-lactide), PMMA (polymethyl methacrylate), PCL (polycaprolactone), HA (Hyaluronic Acid)\n20. Subjects who have taken any of the following medications within 1 week before the application of the investigational medical device or who are scheduled to take them within 3 days after application (however, if the medication is being taken at the time of screening and, in the investigator's judgment, a temporary discontinuation does not pose a medical risk, the individual may participate in the clinical trial after a 10-day wash-out period): \\*Anticoagulants, antiplatelet agents, thrombolytics (e.g., warfarin), oral\u002Finjectable corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) (low-dose aspirin up to 300 mg\u002Fday is permitted), and substances that delay blood coagulation time (such as vitamin E preparations of 400 IU\u002Fday or more, including multivitamins, garlic, and ginkgo biloba extracts).\n21. Subjects who have received systemic corticosteroids or immune-suppressants within 12 weeks of screening.\n22. Subjects who have applied oral or topical preparations or cosmetics with anti-wrinkle effects to the facial area within 12 weeks of screening (however, the use of sunscreen and certain cosmetics such as alpha hydroxyl acids, glycolic acids, retinol, or retinoic acids, which have been continuously used for more than 90 days prior to screening, is permitted).\n23. Subjects who have undergone chemotherapy within 12 weeks of screening.\n24. Subjects who have received botulinum toxin injections in the face within 24 weeks of screening.\n25. Subjects who have taken other investigational drugs or had investigational medical devices applied within 4 weeks of screening.\n26. Pregnant women, women planning to become pregnant during the clinical trial period, or breastfeeding women.\n27. Subjects who, for any other reason, are deemed unsuitable by the investigator for inclusion in this clinical trial.",{"count":112,"type":21},80,[114],"PHASE2","Purpose of this study is the demonstration of safety and efficacy of the dermal fillers DXP01 Face for restoration of moderate to severe nasolabial folds",[117,27],"Dermal Fillers",[119,109],"NASOLABIAL FOLDS","2025-03-13",{"date":122,"type":32},"2025-03-20",{"date":124,"type":21},"2025-04-28",{"date":126,"type":21},"2027-12-01",{"name":128,"class":39},"DEXLEVO"]